Human Stem Cells Institute Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Prikhodko Viktorovich

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	1.4%
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Public Joint-Stock Company "Human Stem Cells Institute" (MCX:ISKJ)

May 09

Is Human Stem Cells Institute (MCX:ISKJ) Using Too Much Debt?

Dec 25

We Wouldn't Rely On Human Stem Cells Institute's (MCX:ISKJ) Statutory Earnings As A Guide

Nov 19

CEO

Prikhodko Viktorovich (63 yo)

no data

Tenure

Mr. Prikhodko Alexander Viktorovich, Ph D., served as Chairman of the Board of Public Joint-Stock Company "Human Stem Cells Institute" since July 30, 2012 until October 2020 and serves as its General Direc...

Human Stem Cells Institute Management

Management criteria checks 0/4

Key information

Recent management updates

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Less than half of directors are independent

Less than half of directors are independent

ISK CHELOVEKA Ordinary Shares to Be Deleted from Other OTC

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Public Joint-Stock Company "Human Stem Cells Institute" announced that it has received RUB 400 million in funding from Limited Liability Company "IceGen 2"

Risks To Shareholder Returns Are Elevated At These Prices For Public Joint-Stock Company "Human Stem Cells Institute" (MCX:ISKJ)

Full year 2020 earnings released: EPS ₽0.97 (vs ₽1.13 in FY 2019)

New 90-day low: ₽34.49

Public Joint-Stock Company "Human Stem Cells Institute" announced that it has received funding from Limited Liability Company "IceGen 2"

New 90-day high: ₽40.30

Is Human Stem Cells Institute (MCX:ISKJ) Using Too Much Debt?

New 90-day high: ₽39.90

Market bids up stock over the past week

Public Joint-Stock Company "Human Stem Cells Institute" (MISX:ISKJ) and Artur Isaev acquired 17.79% interest in GENETICO LLC from RVC Biopharmaceutical Investments, Limited liability Company, managed by RVC (OJSC), Investment Arm.

We Wouldn't Rely On Human Stem Cells Institute's (MCX:ISKJ) Statutory Earnings As A Guide

New 90-day high: ₽35.80

Market bids up stock over the past week

New 90-day high: ₽29.00

Artur Isayev acquired 16.68% stake in Human Stem Cells Institute PJSC (MISX:ISKJ).

New 90-day low - ₽22.80

New 90-day low - ₽24.80

CEO

Tenure